Key Highlights
- Third quarter Revenue was USD 122.98 million against a USD 115.8 million estimate and USD 83.52 million a year earlier.
- Diluted EPS was USD 0.32 against an estimate of USD 0.15, compared with USD 0.10 in the prior-year quarter.
- Net income was USD 17.39 million, and adjusted EBITDA was USD 22.68 million against USD 15.80 million a year earlier.
- Gross Margin was 71% against 70% a year earlier, and cash and cash equivalents were USD 561.5 million.
BillionToOne (NASDAQ:BLLN) reported third quarter revenue of USD 122.98 million, against USD 83.52 million in the same quarter of 2025 and an estimate of USD 115.8 million. Diluted EPS was USD 0.32, against an estimate of USD 0.15. The company sells prenatal and oncology tests built on its single molecule NGS platform, and it described the quarter as one in which more tests were processed at a higher average selling price.
Results, Volume and Pricing
Revenue increased 47%. Delivered and billable test volume rose 25% to approximately 206,000 tests from approximately 165,000, while total tests accessioned were approximately 207,000 against 163,000. Overall average selling price increased 18%. The company said volume growth came from larger prenatal and oncology sales forces, and that the price gain reflected more payor contracts for prenatal tests and its proprietary PLA code. Revenue also included USD 7.6 million tied to services from prior periods, more than half of it from a payor claims reprocessing.
Cost of revenue was USD 35.84 million against USD 25.11 million, and Gross Profit was USD 87.15 million against USD 58.42 million. Overall cost per test increased 10% as sales mix moved toward oncology products, which carry a higher cost per test, though the company said lab efficiencies lowered the variable share of costs of goods sold to 56% from 59%.
Operating Costs, Earnings and Adjusted EBITDA
Research and development expenses were USD 20.22 million against USD 12.95 million, and selling, general and administrative expenses were USD 55.91 million against USD 35.83 million. Management tied the increases to headcount. Income from operations was USD 11.02 million against USD 9.63 million.
Interest income was USD 4.91 million against USD 1.54 million, and a change in the Fair Value of the term Loan was a gain of USD 1.48 million, against a loss of USD 3.94 million. Net Income was USD 17.39 million, or USD 0.37 per basic share and USD 0.32 per diluted share, against USD 5.71 million and USD 0.10 per diluted share. Adjusted EBITDA was USD 22.68 million against USD 15.80 million.
Cash, Debt and Nine-Month Figures
Cash and cash equivalents were USD 561.5 million at September 30, against USD 495.98 million at December 31, with Working Capital of USD 621.5 million. For the nine months, Operating Cash Flow was USD 37.11 million against USD 13.80 million, and financing inflows of USD 40.89 million included a USD 30.0 million draw on the third Tranche of the Oberland debt and USD 12.2 million from option exercises. The company said it was in compliance with all financial covenants.
Nine-month revenue was USD 340.82 million against USD 209.06 million, and net income was USD 43.42 million, or USD 0.81 per diluted share, against USD 1.48 million, or USD 0.03.
Numbers in Context
Revenue of USD 122.98 million sits alongside a gross margin of 71%, adjusted EBITDA of USD 22.68 million and cash of USD 561.5 million, with about 770,000 tests processed in the 12 months to September 30 out of almost two million since launch.
Management named a tissue-free, pan-cancer MRD test with commercial availability targeted for December 2026, and the August 2026 launch of Northstar Origin as a tissue-of-origin add-on. It also cited a pending companion diagnostic indication for its UNITY Fetal Antigen test. The company disclosed that Illumina filed a lawsuit on May 7, 2026 alleging UNITY infringes three patents, which the company said is without merit.
_11_19_2026_19_19_13_574021.jpg)





Please wait processing your request...